Antibiotic-associated adjuvant for multi-resistant bacteria (MRB) control

SAYENS



20 Octobre 2020

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

CONTEXT

Bacteria that are frequently involved in the clinic may be resistant or even multi-resistant to antibiotics (MRB).

The lack of new antibiotic solutions or new adjuvants sometimes leads patients to therapeutic dead-ends that can be fatal.

 

DESCRIPTION

The laboratory has shown that the combination of a calixarene with an antibiotic could give a new threshold of sensitivity to a bacterium resistant to this antibiotic.

This association tested with a large panel of antibiotics on three of the most dangerous MRB (Pseudomonas aeruginosa, E. Coli and Streptococcus aureus multi resistant) concludes that there is a synergy or additivity for some couples on these BMRs.

After having concluded in the non-toxicity of calixarene 1, in vivo investigations will be carried out on mice infected by Pseudomonas aeruginosa and on contaminated murine lungs.

 

COMPETITIVE ADVANTAGES

New adjuvant in antibacterial control
Synergistic or additive action
Non-toxic in murine

 
MARKETS AND APPLICATIONS

Pharmaceutical

 
DEVELOPMENT STAGE

TRL 3 in vitro studies

  

INTELLECTUAL PROPERTY

Patent issued in 2013

 

TARGET PARTNERSHIP

Patent licensing

 

CONTACT

Thomas BLUM

Business Developer

+33 (0)6 17 06 68 07

thomas.blum@sayens.fr

Download the offer Download the offer

Newsletter